Clearmind Medicine Inc. (CMND) shares surged 46.72 percent to $3.59, up $1.14 on Friday, after the clinical-stage biotech company announced the publication of a Japanese patent application related to its proprietary depression treatment technology.
The stock is currently trading at $3.59, compared with a previous close of $2.45 on the Nasdaq. It opened at $3.50 and traded between $3.15 and $4.66 during the session, with volume surging to 41.05 million shares versus average daily volume of 612,955 shares.
Clearmind Medicine Inc. said the patent application covers compositions comprising 5-Methoxy-2-aminoindan (MEAI) for the treatment of depression. The company stated the filing further strengthens its intellectual property portfolio focused on non-hallucinogenic neuroplastogen-derived therapeutics.
Clearmind Medicine shares have traded between $2.10 and $524.00 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.